格隆汇8月18日丨华领医药-B(02552.HK)公布，公司谨定于2025年8月28日(星期四)举行董事会会议，以 考虑及通过集团截至2025年6月30日止的六个月中期业绩，及有关公布，以及处理其他事项。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 董事會召開日期 華領醫藥（「本公司」及其附屬公司「本集團」）董事會（「董事會」）茲通告，本公司 謹定於2025年8月28日（星期四）舉行董事會會議，以考慮及通過本集團截至2025 年6月30日止的六個月中期業績，及有關公佈，以及處理其他事項。 承董事會命 行政總裁兼執行董事 陳力博士 香港，2025年8月18日 於本公告日期，董事會成員包括執行董事陳力博士、林潔誠先生及張怡博士；非 執行董事Robert Taylor Nelsen先生；以及獨立非執行董事William Robert Keller先 生、徐耀華先生及張耀樑先生。 HUA MEDICINE 華領醫藥 （於開曼群島註冊成立的有限公司） （股份代號：2552） ...

Core Insights - Chinese innovative drugs currently account for 38% of the global market [1] - In the previous year, 39 innovative drugs were launched, while 30 have already been launched in the first half of this year [1] - China is capable of developing globally first-in-class innovative drugs, exemplified by Hualing Pharmaceutical's Huatangning, which can reverse diabetes and prevent complications [1] Industry Summary - The growth of innovative drug development in China is significant, with a notable increase in the number of drugs launched annually [1] - The successful market entry of innovative drugs like Huatangning demonstrates China's potential in advanced scientific concepts and technologies [1] - The inclusion of innovative drugs in China's medical insurance indicates a supportive regulatory environment for the pharmaceutical industry [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 華領醫藥 | | | | | | 呈交日期: | 2025年8月6日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 02552 | 說明 | 普通股 | | | | | 法定/註冊股份數目 | 面值 | | 法定/註冊股本 | | | --- | --- | --- | --- | --- | --- | | 上月底結存 | 2,000,000,000 | USD | 0.001 | USD | 2,000,000 | | 增加 / 減少 (-) | | | | USD | | | 本月底結存 | 2,000,000,000 | USD | 0. ...

每经AI快讯，8月6日，截至发稿，晶泰控股(02228.HK)涨15%、华领医药-B(02552.HK)涨4.62%、歌礼 制药-B(02509.HK)涨2.35%。 ...

Group 1 - The Hong Kong biotechnology stocks collectively rose, with notable increases in several companies' stock prices [1][2] - Beihai Kangcheng-B saw a rise of nearly 19%, while other companies like Gilead Sciences-B and Ascentage Pharma-B also experienced significant gains of over 15% and 9% respectively [1][2] - The overall trend indicates a positive sentiment in the biotechnology sector, with multiple companies achieving gains of over 5% [1][2] Group 2 - Specific stock performance includes: Beihai Kangcheng-B at 18.99% increase, Gilead Sciences-B at 15.30%, and Ascentage Pharma-B at 9.48% [2] - The market capitalization of these companies varies significantly, with Gilead Sciences-B at approximately 11.477 billion and Ascentage Pharma-B at about 29.86 billion [2] - Other notable performers include Jiahua Bio-B and Beikang Medical-B, both showing increases of over 7% [1][2]

Group 1 - China Biopharmaceutical announced a successful collaboration progress with Merck on LM-299, expecting to receive a $300 million technology transfer milestone payment soon [1] - The technology transfer for LM-299 was completed in July 2025, with Merck confirming the milestone payment in the third quarter [1] - CSPC Pharmaceutical reached an exclusive licensing agreement with Madrigal for the GLP-1 receptor agonist SYH2086, with a total deal value of up to $20.75 billion [2] Group 2 - Eli Lilly's drug Mounjaro (tirzepatide injection) received approval from China's National Medical Products Administration for a new indication to improve blood sugar control in adults with type 2 diabetes [3] - Hualan Pharmaceutical expects a profit of approximately RMB 1.184 billion for the first half of the year, following the successful transfer of commercialization tasks for Huataning [4] - WuXi AppTec reported a 101.92% increase in net profit to RMB 8.561 billion for the first half of the year, with revenue growth of 20.64% to RMB 20.799 billion [5] Group 3 - Heng Rui Medicine signed a collaboration agreement with GSK to advance innovative therapies in respiratory, autoimmune, inflammation, and oncology fields, with a potential total value of approximately $12 billion [6][7] - GSK will pay Heng Rui a $500 million upfront payment, with potential future milestone payments based on successful development and sales [7]

Core Viewpoint - Hualing Pharmaceutical reported a profit of approximately 1.184 billion RMB in the first half of the year, marking its first profit since its listing, a significant turnaround from a loss of 140 million RMB in the same period last year [1][2]. Group 1: Financial Performance - The profit growth is largely attributed to a one-time gain from terminating an exclusive promotion agreement with Bayer, resulting in a reversal of unamortized contract liabilities amounting to 1.2435 billion RMB [2][4]. - Hualing Pharmaceutical's revenue is expected to be scrutinized in the future, as the one-time gain does not indicate sustainable growth [4]. - The company's sales of its main product, Huatangning, reached approximately 1.764 million boxes with a net sales revenue of about 217.4 million RMB, reflecting a 111.8% increase compared to the same period last year [6][10]. Group 2: Product and Market Strategy - Hualing Pharmaceutical's main product, Huatangning, is currently the only commercialized drug, targeting type 2 diabetes patients [8]. - The company has successfully transitioned to a self-managed sales model, having built its own sales team for the first time, which has contributed to the doubling of product sales [6][7]. - The gross profit margin increased to approximately 54.2% in the first half of the year, up from 46.5% in the same period last year, attributed to improved production efficiency and reduced unit production costs [6]. Group 3: Future Outlook - Hualing Pharmaceutical aims to achieve a sales net income of 1 billion RMB by 2027, indicating a long-term growth strategy [7]. - The company is in the early stages of its commercial sales journey, with significant potential for growth in the diabetes medication market [10].

与单纯增加胰岛素剂量相比，联合使用替尔泊肽可显著改善血糖控制、减少胰岛素用量、降低体重，且不增加低血糖风险，为胰岛素治疗效果不佳的患者提 供了更优的治疗选择。 对于新增联合疗法适应症的获批，北京医院国家老年医学中心内分泌科主任郭立新教授表示："在研究中，替尔泊肽在既往胰岛素治疗的中国2型糖尿病患者 中，与安慰剂相比，在血糖控制和体重减轻方面展现出具有临床意义的显著改善，且未增加低血糖风险。" 复旦大学附属中山医院内分泌科主任李小英教授此前告诉第一财经记者，GLP-1药物联合胰岛素控制糖尿病是临床上正在探索的一个具有潜力的方向。 胰岛素为何不可或缺？ 7月28日，礼来公司的GLP-1类药物替尔泊肽注射液（商品名：穆达峰）又添新增适应症——联合胰岛素治疗，用于在饮食控制和运动基础上，改善成人2型 糖尿病（T2DM）患者的血糖控制。 此前，替尔泊肽已经在中国获批三项适应症，包括用于成人2型糖尿病的血糖控制，长期体重管理以及阻塞性睡眠呼吸暂停。 在我国，针对糖尿病的治疗，胰岛素的使用率相对较高，但患者整体血糖控制率仍不理想，且胰岛素治疗常伴随低血糖风险及体重增加等不良反应。 与单纯增加胰岛素剂量相比，联合使用替尔泊肽 ...

Core Viewpoint - Hualing Pharmaceutical Technology (Shanghai) Co., Ltd. reported a profit of approximately 1.184 billion yuan for the first half of the year, marking its first profitable period [1] Group 1: Financial Performance - The company sold approximately 1.764 million boxes of Huadongning, generating a sales revenue of about 217 million yuan in the first half of the year [1] - In comparison, the sales volume for the same period in 2024 was about 846,000 boxes, with a sales revenue of approximately 102.7 million yuan, indicating a sales growth of 111.8% while maintaining the same price per box [1] - As of June 30, 2025, the gross profit was around 118 million yuan, with a gross margin of approximately 54.2%, compared to a gross profit of about 47.8 million yuan and a gross margin of 46.5% in 2024 [1] Group 2: Strategic Insights - The increase in gross margin is attributed to improved production efficiency and higher output, leading to a decrease in unit production costs [1] - The CEO, Dr. Chen Li, emphasized the strong growth momentum of Huadongning and the establishment of a sales team that accelerates market penetration, instilling confidence for future profitability [1] - The company plans to continue exploring market potential in personalized diabetes treatment and complications through research and development innovation and capacity enhancement [1]